retatrutide or tirzepatide vs Tirzepatide: GLP-1, GIP & Glucagon Retatrutide vs Tirzepatide Compared |

Novo will pay Septerna around $200 million in upfront and near-term performance milestone payments, with up to $2.2 billion promised based on the projects long-term performance

However, with the advent of incretin treatment, there are now pharmacological options that result in weight loss of 15 to 20% bodyweight, which approaches that achieved with bariatric surgery, and substantial cardiovascular benefit

Sustainability Concerns : The requirement for potentially lifelong therapy, combined with rapid weight regain upon discontinuation, raises questions about long-term sustainability and practical implementation

The bigger factor is supply chain proximity

Batth, T

GLP-1 receptor agonists GLP-1 receptor monoagonists According to their pharmacodynamics and pharmacokinetic properties, the GLP-1RAs are categorized as either short-acting or long-acting agents